MedTrace Logo

The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07780578 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-08-25

No results posted yet for this study

Summary

This study is a single arm study to access the anti-tumor efficacy and safety of Andamertinib plus Anlotinib in patients with locally advanced or metastatic non-small cell lung cancer previously treated with third-generation EGFR-TKI.

Conditions

  • Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

Interventions

DRUG

Andamertinib

Andamertinib: 160mg, QD, Q3W

DRUG

Anlotinib

Anlotinib: 12mg/10mg, QD, d1-d14, Q3W

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Jialei Wang · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-09-30
Completion
2029-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07780578 on ClinicalTrials.gov